Device approved for first nasal rescue treatment for frequent seizure activity
AptarGroup, Inc. announced that its patented UnidoseLiquid System is the device delivering the first and only nasal rescue treatment approved by the U.S. Food and Drug Administration (FDA), which has recently launched in the U.S. to treat acute repetitive seizures in people living with epilepsy. This ready-to-use rescue treatment can be used when and where a seizure cluster occurs.
Noble International, recently acquired by Aptar and part of Aptar Pharma’s services offering, developed a trainer device in partnership with the customer to be used as part of a patient onboarding program for this new drug product.
Stephan Tanda, Aptar President and CEO, stated, “This approval and successful market launch further demonstrate the broad potential for Aptar’s patient-friendly drug delivery solutions and service offerings which help our pharmaceutical customers address unmet healthcare needs. We are pleased to offer a broad portfolio of innovative technologies and wide array of services to meet the highest quality standards of the pharmaceutical industry.”
Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily and can be administered by a non-healthcare professional to a patient during or after a seizure. During such an event, the patient or caregiver presses a small plunger on the bottom of the device to release the drug in a single spray into the nostril, where the drug can be quickly absorbed via the nasal mucosa.
